Plaintiff Hospira Incorporated
1
appeals from summary judgment granted in favor of Defendant AlphaGary Corporation on Hospira’s claims for fraud, negligent misrepresentation, violations of the Unfair and Deceptive Trade Practices Act, and third party beneficiary breach
of contract. Hospira also appeals from the 16 February 2006 order dismissing its negligence claim and from the 16 August 2007 order denying its motion to reinstate the negligence claim in light of
Lord v. Customized Consulting Speciality, Inc.,
Hospira manufactures medical devices known as sight chambers, which are small transparent tubes that attach to intravenous (IV) lines and allow the monitoring of fluids. Hospira sells sight chambers to healthcare providers as part of IV administration kits. To manufacture the sight chambers, Hospira uses a specially formulated polyvinyl chloride (PVC) compound known as Ashland Dry-Blend (ADB) or 50-0218. ADB is a “radiation
Hospira previously formulated and pelletized ADB, and molded the sight chambers itself; however in 1999, Hospira began to contract with Moll Industries, Inc. to manufacture its sight chambers. In late 2001, Hospira retained AlphaGary to pelletize the ADB for use in the molding process. AlphaGary signed a specification letter, prepared by Hospira, for the production of ADB pellets, material number 75-1648. The letter included a continuing guarantee that the pellets be manufactured in accordance with Hospira’s specifications. The letter did not address the specifications for pellets ordered by third party vendors.
In November 2001, Hospira again retained Moll to manufacture some of its sight chambers. However, Hospira did not supply the ADB pellets directly to Moll as it had done in previous orders; rather, Hospira instructed Moll to purchase the pellets from AlphaGary. But, instead of using ADB to make the pellets sold to Moll, AlphaGary used its own proprietary non-radiation grade PVC resin. Thereafter, Moll, using the pellets provided by AlphaGary, manufactured millions of sight chambers, which Hospira purchased and incorporated into its IV administration kits. Over time, Hospira learned that the cham bers were becoming severely discolored after repeated sterilization. Upon discovering that the pellets Moll used to make the chambers were not “radiation grade” ADB, Hospira recalled, replaced, and destroyed the sight chambers and accompanying kits.
On 5 April 2005, Hospira brought an action against AlphaGary for fraud, negligent misrepresentation, negligence, estoppel, third party beneficiary breach of contract, and violation of the North Carolina Unfair and Deceptive Trade Practices Act. Hospira alleged that AlphaGary intentionally concealed its use of an “unapproved” compound substitute and made false and misleading statements to Moll. and Hospira’s management in an attempt to cover-up the switch. In response, AlphaGary moved to dismiss the action under Rule 12(b)(6) of the North Carolina Rules of Civil Procedure. By order dated 16 February 2006, the trial court granted AlphaGary’s motion regarding Hospira’s claim for negligence and estoppel but denied its motion regarding the remaining four claims.
On 1 May 2007, AlphaGary moved for summary judgment on the remaining claims. The trial court granted summary judgment for AlphaGary and denied Hospira’s Rule 60(b)(6) motion to reinstate its negligence claim in light of Lord. Hospira appeals arguing that the trial court erred by (I) granting summary judgment in favor of AlphaGary and (II) failing to reinstate its negligence claim, originally dismissed as barred under the economic loss rule, in light of Lord.
I.
This Court reviews an appeal from summary judgment to determine “whether there is any genuine issue of material fact and whether the moving party is entitled to a judgment as a matter of law.”
Bruce-Terminix Co. v. Zurich Ins. Co.,
In its appeal, Hospira argues that the trial court erred in granting summary judgment for AlphaGary on its claims of (A) fraud and neg ligent misrepresentation; (B) violation of the North Carolina Unfair and Deceptive Trade Practices Act, and (C) third party beneficiary breach of contract. We disagree.
A.
Hospira first argues that the trial court erred by granting summary judgment
Although the record reflects significant communications between AlphaGary and Moll, there is no evidence in the record that AlphaGary concealed or misrepresented to Hospira the composition of the pellets supplied to Moll or that AlphaGary acted with intent to deceive either party. An essential element of actionable fraud is that the false representation or concealment be made
to the party acting thereon. See, e.g., Shreve v. Combs,
Nonetheless, Hospira argues that, based on the specification letter and continuing guarantee, AlphaGary agreed to follow certain specifications and that the agreement applied to all purchases of “75-1648” or ADB pellets, whether by Hospira or a third party vendor. However, the record reflects that the specification letter was binding only as to transactions between Hospira and AlphaGary. The specification letter includes nothing to indicate that the specifications were also intended to apply to transactions between AlphaGary and Moll. Accordingly, this argument is without merit.
Further, Hospira argues that AlphaGary’s misrepresentations, conveyed through Moll, are actionable. Hospira relies on the Court’s holding in
Rowan County Bd. of Education v. U.S. Gypsum Co.,
Here, there is no evidence to suggest that Moll acted as Hospira’s agent in purchasing the compounds for pelletization from AlphaGáry; in fact, Hospira denied that Moll was its agent. Still, Hospira points out that the decision in
Rowan County
does not explicitly define “agent” or analyze the degree of control the school district exercised over the architect. However, we believe that the context of the decision indicates that the Court intended to give the term “agent” — a term of art — its legal meaning: “one who, with another’s authority, undertakes the transaction of some business or the management of some affairs on behalf of such other, and to render an account of it.”
Phelps-Dickson Builders, L.L.C. v. Amerimann Partners,
Similarly, Hospira’s claim for negligent misrepresentation fails. To establish a claim for negligent misrepresentation, a party must show that he: “[(1)] justifiably relies [(2)] to his detriment [(3)] on information prepared without reasonable care [(4)] by one who owed the relying party a duty of care.”
Raritan River Steel Co. v. Cherry,
Bekaert & Holland,
In
Raritan,
the plaintiff brought a negligent misrepresentation suit against a defendant, a certified public accountant, who published a report containing financial information about a company to whom the plaintiff later extended credit.
Id.
at 200,
Here, evidence in the record suggests that while Hospira may have relied on the certifications provided by Moll, Moll was not a passive intermediary. The specification numbers and information provided by Moll to Hospira were materially inconsistent with the certifications AlphaGary provided to Moll. Moll’s quality supervisor testified that Moll’s certification records were not properly and consistently prepared, noting that the raw material descriptions contained in the certifications prepared by Moll often varied within the same lot of material. Indeed, Hospira presented no evidence of direct reliance on AlphaGary’s certification documents.
In sum, under a theory of negligent misrepresentation, liability cannot be imposed when the plaintiff does not directly rely on information prepared by the defendant, but instead relies on altered information provided by a third party. Because the record fails to show a direct reliance on any statements or documents from AlphaGary about the nature of the compounds then sold to it by Moll, we uphold the trial court’s grant of summary judgment on this issue.
B.
Hospira next argues that the trial court erred in granting summary judgment for AlphaGary on Hospira’s claim for unfair and deceptive trade practices. We disagree.
“In order to establish a
prima facie
claim for unfair trade practices, a plaintiff must show: (1) defendant committed an unfair or deceptive act or practice, (2) the action in question was in or affecting commerce, and (3) the act proximately caused injury to the plain
tiff.”
Dalton v. Camp,
C.
Hospira further argues that the trial court erred in granting summary judgment in favor of AlphaGary on its third party beneficiary breach of contract claim. “To establish a claim based on the third party beneficiary contract doctrine, a complaint’s allegations must show: (1) the existence of a contract between two other persons; (2) that the contract was valid and enforceable; and (3) that the contract was entered into for his
direct,
and not incidental, benefit.”
Leasing
Corp. v. Miller,
Hospira contends that it provided sufficient evidence that the contracts between Moll and AlphaGary were for its direct benefit. However, Hospira provides no evidence to suggest that it was an intended beneficiary of the contract between Moll and AlphaGary. The invoices, emails, and phone communications regarding the transactions are exclusively between representatives from Moll and AlphaGary. They do not involve the type of “active and direct dealings” which courts have required to confer third party beneficiary status on a party not contemplated by the contract itself.
See CF Industries v. Transcontinental Gas Pipe Line,
Additionally, the facts presented here are similar to
Vogel v. Reed Supply Co.,
In our view the subcontract here was not intended for the benefit of the plaintiff landowner. Plaintiff benefits only incidentally or indirectly because performance of the subcontract was rendered in fulfillment of Reed’s obligation to the general contractor. Hence, any benefit derived from the subcontract by the landowner would necessarily accrue indirectly, i.e., through the general contractor.
Id.
at 129,
II.
Finally, Hospira contends that the trial court erred in failing to reinstate its negligence claim, originally dismissed as barred under the economic loss rule, in light of the Court’s decision in Lord 2 We agree.
In
Lord,
plaintiffs brought suit against defendants for negligence, including the group referred to as “84 Lumber Defendants,” who were subcontracted to provide the wooden trusses used in the construction of the plaintiffs’ residence.
Lord,
As previously stated by this Court, “[t]he rationale for the economic loss rule is that the sale of goods is accomplished by contract and the parties are free to include, or exclude, provisions as to the parties’ respective rights and remedies, should the product prove to be defective.” Thus, the rule encourages contracting parties to allocate risks for economic loss themselves, because the promisee has the best opportunity to bargain for coverage of that risk or of faulty workmanship by the promisor.
Id.
at 639,
Given the holding in Lord and both parties’ agreement that there was no contract between Hospira and AlphaGary, we hold that the trial court erred in failing to reinstate Hospira’s negligence claim.
Affirmed in part; Reversed and remanded in part.
Notes
. Before 12 April 2004, Hospira Incorporated was known as Abbott Laboratories’ Hospital Products Division.
. Although Hospira assigns the original motion to dismiss its claim for negligence in its assignments of error and arguments in its brief, Hospira only argues that the decision was in error in light of Lord. Accordingly, this Court need only consider the order denying Hospira’s motion to reinstate.
